



ASX ANNOUNCEMENT

Henry Schein Expands Distribution Partnership for FebriDx®

Rapid point-of-care test available to health care practitioners in the Netherlands

MELBOURNE, Australia (16 August 2023) – Lumos Diagnostics (ASX: LDX), (“Lumos” or the “Company”) a leader in rapid, point-of-care (POC) diagnostic technologies, has signed an agreement with Henry Schein B.V. for the FebriDx® point-of-care test. The agreement further expands the distribution of FebriDx through Henry Schein’s Medical business to include the Netherlands.

FebriDx® is a rapid POC test to differentiate a viral from bacterial acute respiratory infection. FebriDx delivers results in 10 minutes from fingerstick blood and can be used to help rapidly and accurately manage infectious patients in Primary Care, Urgent Care, Emergency Dept, Paediatric and other Outpatient settings. Henry Schein B.V. in the Netherlands, which is part of Henry Schein, Inc. (Nasdaq: HSIC), the world’s largest provider of health care solutions to office-based dental and medical practitioners, will sell the FebriDx test to the company’s Medical customers throughout the Netherlands with sales and marketing activities commencing immediately.

“At Henry Schein, our goal is to help health care professionals enhance efficiencies so they can focus on delivering quality care. We are therefore delighted to expand our distribution of FebriDx beyond the UK, Spain, and Portugal to include the Netherlands,” said Alain Nijsing, General Manager of Henry Schein’s Medical business in the Netherlands. “

*“It is great to see the increased interest in our FebriDx test from one of the world’s largest distributors of healthcare and medical products,” said **Doug Ward, CEO and Managing Director** of Lumos Diagnostics. “Henry Schein has been a terrific and supportive partner for Lumos despite the headwinds the pandemic generated for products such as FebriDx. With our recent US clearance and the growing commercial interest in FebriDx, we are now preparing production of FebriDx to meet the anticipated growing demand for the product, and further refining our US and global sales strategy. It is very exciting to have Henry Schein as part of this strategy with their expanded distribution coverage for FebriDx in the European market.”*

-Ends-

This announcement has been approved by the Lumos Disclosure Committee.



About Lumos Diagnostics

Lumos Diagnostics specializes in rapid, cost-effective, and complete point-of-care (POC) diagnostic test technology to help healthcare professionals more accurately diagnose and manage medical conditions. Lumos offers customized assay development and manufacturing services for POC tests and proprietary digital reader platforms. Lumos also directly develops, manufactures, and commercializes novel Lumos-branded POC tests that target infectious and inflammatory diseases.

For more information visit lumosdiagnostics.com.

About Henry Schein, Inc.

Henry Schein B.V. is part of Henry Schein, Inc. (Nasdaq: HSIC), a solutions company for health care professionals powered by a network of people and technology. With more than 23,000 Team Schein Members worldwide, the Company's network of trusted advisors provides more than 1 million customers globally with more than 300 valued solutions that help improve operational success and clinical outcomes. The Company's Business, Clinical, Technology, and Supply Chain solutions help office-based dental and medical practitioners work more efficiently so they can provide quality care more effectively. These solutions also support dental laboratories, government and institutional health care clinics, as well as other alternate care sites.

Henry Schein operates through a centralized and automated distribution network, with a selection of more than 300,000 branded products and Henry Schein corporate brand products in our distribution centers. A FORTUNE 500 Company and a member of the S&P 500® index, Henry Schein is headquartered in Melville, N.Y., and has operations or affiliates in 33 countries and territories.

For more information, visit Henry Schein at the company's corporate website www.henryschein.com or at www.henryschein.nl for the Netherlands.

Forward-Looking Statements

This announcement contains forward-looking statements, including references to forecasts. Forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions, and other important factors, many of which are beyond Lumos' control and speak only as of the date of this announcement. Readers are cautioned not to place undue reliance on forward-looking statements.

Media Contacts:

Matthew Wright – Australia, Lumos
Director, NWR Communications
matt@nwrcommunications.com.au
+61 (0) 451 896 420

Stefanie Fleige – EMEA, Henry Schein
Director, Corporate Media Relations
Stefanie.Fleige@henryschein.de
+49 40 656 68 691



Investor Contact:

Matthijs Smith – Lumos Diagnostics
ir@lumosdiagnostics.com
+61 3 9087 1598

Company Registered Office:

Lumos Diagnostics Holdings Ltd
Level 4, 100 Albert Rd
South Melbourne, VIC 3205
+61 3 9087 1598